Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Efrat Dotan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5762-512X; OpenAlex author ID A5072144086. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 5, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers, 1 trial · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 23

  1. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  2. Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer. First author DOI 10.1200/op-25-00980↗
  3. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  4. Investigation of Treatment-Related Disparities in Metastatic Pancreatic Cancer Patients Using Real-World Data. Co-author DOI 10.1002/cam4.71108↗
  5. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. First author DOI 10.1007/s12029-025-01188-x↗
  6. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Last author DOI 10.1089/jpm.2024.0313↗
  7. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and … Co-author DOI 10.1016/j.jgo.2023.101474↗
  8. Venous thromboembolism in metastatic pancreatic cancer. Co-author DOI 10.1111/ejh.13955↗
  9. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10219-3↗
  10. Predicting positive peritoneal cytology in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03471-9↗
  11. Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach. First author DOI 10.1007/s11864-021-00892-7↗
  12. Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. Last author DOI 10.1093/jncics/pkab074↗
  13. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  14. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  15. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. Last author DOI 10.1016/j.jgo.2019.12.013↗
  16. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  17. Investigating disparities: the effect of social environment on pancreatic cancer survival in metastatic patients. Co-author DOI 10.21037/jgo-20-39↗
  18. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. First author DOI 10.1016/j.jgo.2018.11.001↗
  19. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  20. Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.21037/apc.2018.05.01↗
  21. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  22. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000619↗
  23. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience. First author DOI 10.1016/j.jgo.2015.08.001↗

Trials 1

  1. Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreat… Principal investigator NCT04233866↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shannon M. Lynch · 5 shared papers, 2020–2025 · strength 1.00
  2. Sanjay S. Reddy · 4 shared papers, 2021–2025 · strength 0.73
  3. Joshua E. Meyer · 4 shared papers, 2021–2025 · strength 0.73
  4. Namrata Vijayvergia · 5 shared papers, 2015–2025 · strength 0.66
  5. Ramy Sedhom · 1 shared paper, 2026 · strength 0.63
  6. Steven J. Cohen · 6 shared papers, 2015–2022 · strength 0.58
  7. Dana Backlund Cardin · 6 shared papers, 2017–2021 · strength 0.52
  8. Arthur Winer · 2 shared papers, 2021 · strength 0.50
  9. Eileen Mary O'Reilly · 4 shared papers, 2017–2026 · strength 0.50
  10. Anush Narasimhan Sridharan · 2 shared papers, 2025 · strength 0.49
  11. Edna Cukierman · 2 shared papers, 2025–2026 · strength 0.44
  12. Lauren Laderman · 2 shared papers, 2023–2025 · strength 0.37
  13. Igor A. Astsaturov · 3 shared papers, 2016–2025 · strength 0.36
  14. Andrew H. Ko · 4 shared papers, 2017–2025 · strength 0.35
  15. Vincent M. Chung · 4 shared papers, 2017–2025 · strength 0.35
  16. Lavanya Aluri · 1 shared paper, 2025 · strength 0.28
  17. Marsha Reyngold · 2 shared papers, 2021–2025 · strength 0.24
  18. Vinod P. Balachandran · 1 shared paper, 2026 · strength 0.24
  19. Miriam Klauß · 1 shared paper, 2026 · strength 0.24
  20. Thierry Conroy · 1 shared paper, 2026 · strength 0.24
  21. Susanne Roth · 1 shared paper, 2026 · strength 0.24
  22. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.24
  23. Minoti Vivek Apte · 1 shared paper, 2026 · strength 0.24
  24. Núria Malats Riera · 1 shared paper, 2026 · strength 0.24
  25. Alison P. Klein · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.